<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00276640</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000454506</org_study_id>
    <secondary_id>2005-005377-29</secondary_id>
    <nct_id>NCT00276640</nct_id>
  </id_info>
  <brief_title>Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas</brief_title>
  <acronym>SIOP-LGG-2004</acronym>
  <official_title>Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Societe Internationale d'Oncologie Pediatrique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Societe Internationale d'Oncologie Pediatrique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in&#xD;
      chemotherapy, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying giving radiation therapy or combination chemotherapy&#xD;
      to see how well it works in treating patients with clinically or radiologically progressive&#xD;
      low-grade gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Provide a comprehensive treatment strategy for children and adolescents with low-grade&#xD;
           glioma of all tumour locations and histologies.&#xD;
&#xD;
        -  Provide standardized treatment indication and treatment recommendations for non-surgical&#xD;
           therapy in children and adolescents with low grade glioma without and with associated&#xD;
           neurofibrosis-type 1 (NF1) at diagnosis or after observation.&#xD;
&#xD;
        -  Determine overall, event-free, and progression-free survival.&#xD;
&#xD;
        -  Radiotherapy arm: a. Determine progression free survival in older children without NF1&#xD;
           treated with radiotherapy using modern techniques for planning and treatment. b.&#xD;
           Determine the reduction of the rate and intensity of possible late effects of therapy to&#xD;
           the organs at risk by optimized planning and treatment.&#xD;
&#xD;
        -  Chemotherapy arm: a. Determine progression free survival for younger children without&#xD;
           NF1 treated with chemotherapy and randomized to either the 2-drug or the 3-drug&#xD;
           induction regimen. b. Determine the distribution of response at week 24 (after&#xD;
           induction) for younger children without NF1 treated with chemotherapy and randomized to&#xD;
           either the 2-drug or the 3-drug induction regimen. c. Determine progression free&#xD;
           survival for children with NF1treated with chemotherapy.&#xD;
&#xD;
        -  Determine the influence of clinical and histological findings on overall survival,&#xD;
           progression-free and event-free survival in these patients.&#xD;
&#xD;
        -  Determine prospectively the late effects of tumor and therapy in these patients.&#xD;
&#xD;
      OUTLINE: This is a partially randomized, open-label, multicenter study.&#xD;
&#xD;
      Children with completely resected tumors, incompletely resected tumors, or those with&#xD;
      clinically/neuroradiologically diagnosed tumors, who do not have severe symptoms at&#xD;
      diagnosis, are only observed during follow-up.&#xD;
&#xD;
      Children with unresectable/incompletely-resectable tumors, or those with relapsed disease and&#xD;
      those observed following incomplete initial resection or neuroradiologic diagnosis and&#xD;
      clinical and/or neuro-radiologic progression receive non-surgical therapy. This non-surgical&#xD;
      therapy is either chemotherapy (for children younger than 8 years and those with&#xD;
      neurofibrosis-type 1 [NF1]) or radiotherapy (for children older than 8 years).&#xD;
&#xD;
        -  Chemotherapy: Within the chemotherapy arm, patients without NF1 are randomized to&#xD;
           receive 1 of 2 induction chemotherapy regimens. Patients with NF1 receive the two-drug&#xD;
           induction therapy as in arm I.&#xD;
&#xD;
             -  Arm I (two-drug induction therapy [vincristine-carboplatin] ): Patients receive&#xD;
                induction therapy comprising vincristine IV on day 1 of weeks 1-10 and weeks 13,&#xD;
                17, and 21 and carboplatin IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 17,&#xD;
                and 21.&#xD;
&#xD;
             -  Arm II (three-drug induction therapy [vincristine-carboplatin-etoposide]): Patients&#xD;
                receive vincristine and carboplatin as in two-drug induction therapy. Patients also&#xD;
                receive etoposide IV over 1 hour on days 1-3 of weeks 1, 4, 7, and 10.&#xD;
&#xD;
      Beginning in week 25, all patients in the chemotherapy arm receive consolidation therapy&#xD;
      comprising vincristine IV on days 1, 8, and 15 and carboplatin IV over 1 hour on day 1.&#xD;
      Treatment repeats every 6 weeks for 9 courses. Patients experiencing disease progression or&#xD;
      an allergic reaction to carboplatin receive vincristine IV on days 1, 8, and 15 and either&#xD;
      cyclophosphamide IV over 1 hour on day 1 or cisplatin IV over 3 hours on days 1 and 2.&#xD;
      Treatment repeats every 6 weeks for 5 courses. All patients in the chemotherapy arm receive a&#xD;
      total of 18 months of treatment.&#xD;
&#xD;
        -  Radiotherapy: Conventional external beam fractionated radiotherapy is given at standard&#xD;
           doses for children receiving radiotherapy. Brachytherapy can be given, if tumors are&#xD;
           suitable for this type of treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 10 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 520 patients will be accrued for the randomized arm of this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2004</start_date>
  <completion_date type="Actual">May 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>week 24, and at 1, 3, and 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>week 24 and at 1, 3, and 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>week 24 and at 1, 3, and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response week 24</measure>
    <time_frame>week 24</time_frame>
    <description>radiological response to therapy (chemotherapy or radiation therapy)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3417</enrollment>
  <condition>Primary Central Nervous System Neoplasms</condition>
  <arm_group>
    <arm_group_label>vincristine, carboplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard chemotherapy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vincristine, carboplatin, etoposide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intensified induction chemotherapy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiation therapy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group: wait and see strategy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine, carboplatin</intervention_name>
    <description>vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21&#xD;
carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21</description>
    <arm_group_label>vincristine, carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine, carboplatin, etoposide</intervention_name>
    <description>vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21&#xD;
carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21&#xD;
etoposide: 100 mg/m² i.v., week 1,4,7,10</description>
    <arm_group_label>vincristine, carboplatin, etoposide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks&#xD;
spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks</description>
    <arm_group_label>radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed low-grade glioma, of 1 of the following histologic subtypes:&#xD;
&#xD;
               -  Pilocytic astrocytoma I° and variants&#xD;
&#xD;
               -  Subependymal giant cell astrocytoma I°&#xD;
&#xD;
               -  Dysembryoplastic neuroepithelial tumor I°&#xD;
&#xD;
               -  Desmoplastic infantile ganglioglioma I°&#xD;
&#xD;
               -  Ganglioglioma I° and II°&#xD;
&#xD;
               -  Pleomorphic xanthoastrocytoma II°&#xD;
&#xD;
               -  Oligodendroglioma II°&#xD;
&#xD;
               -  Oligoastrocytoma II°&#xD;
&#xD;
               -  Astrocytoma II°&#xD;
&#xD;
                    -  Fibrillary astrocytoma II°&#xD;
&#xD;
                    -  Protoplasmatic astrocytoma II°&#xD;
&#xD;
                    -  Gemistocytic astrocytoma II°&#xD;
&#xD;
          -  Children with chiasmatic-hypothalamic tumors may be eligible without histological&#xD;
             diagnosis, if neuroradiologic findings meet unequivocal criteria for the presence of a&#xD;
             low-grade glioma&#xD;
&#xD;
          -  Primary tumor localization: intracranial and/or spinal cord&#xD;
&#xD;
               -  No diffuse intrinsic tumors of the pons, even if histologically an astrocytoma I°&#xD;
                  or II° is diagnosed&#xD;
&#xD;
                    -  Exception: pontine glioma II° in neurofibromatosis type 1 (NF1) disease&#xD;
                       allowed&#xD;
&#xD;
          -  Children presenting with disseminated low-grade glioma will be eligible for the study&#xD;
&#xD;
          -  All eligible patients without NF1 disease receiving chemotherapy as their first&#xD;
             nonsurgical therapy are eligible for randomization&#xD;
&#xD;
          -  Children are eligible for the trial regardless of the presence of associated genetic&#xD;
             disease: NF1 disease will be the prominent one, all children with NF1 disease are&#xD;
             entered into the study arm III in case of an indication for nonsurgical therapy&#xD;
&#xD;
          -  Patients presenting with rare intracranial neoplasms of low-grade malignancy, but&#xD;
             nonglial origin, may be followed according to the low-grade glioma strategy, but they&#xD;
             are not subject of this therapy trial.&#xD;
&#xD;
               -  Data from these patients may be registered to learn about those therapeutic&#xD;
                  interventions which may prove useful to these patients and to develop separate&#xD;
                  strategies in the future&#xD;
&#xD;
               -  Patients with choroid plexus papilloma should be entered into the SIOP-CPT study&#xD;
                  (Prof. Dr. J. Wolff, M.D. Anderson Cancer Center, Houston, Texas)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No preexisting impairments of health status, making the conduct of the study&#xD;
             impossible or ethically unwise&#xD;
&#xD;
          -  No evidence of pregnancy or lactation period&#xD;
&#xD;
          -  Pregnancy has to be prevented in fertile adolescent girls during chemotherapy by&#xD;
             reliable contraception methods (e.g., hormonal contraception)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  The tumor should not be pretreated with chemotherapy or radiotherapy&#xD;
&#xD;
               -  Children treated with chemotherapy or radiotherapy prior to entering the study&#xD;
                  will be evaluated separately&#xD;
&#xD;
                    -  Previous treatment with steroids is not considered a chemotherapeutic&#xD;
                       treatment&#xD;
&#xD;
          -  Surgery of any type and extent allowed&#xD;
&#xD;
               -  Prior surgical resection of the tumor allowed&#xD;
&#xD;
          -  Participation in another clinical study concurrently with this study (e.g.,&#xD;
             endocrinologic study) allowed provided it is not interfering with the present&#xD;
             treatment strategy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  Concurrent medication for associated or other conditions (e.g., hormone replacement,&#xD;
             anticonvulsants) that does not containing cytostatic drugs allowed&#xD;
&#xD;
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Age: children and adolescents up to the completion of the 18th year of life.&#xD;
&#xD;
          -  Histology: low grade glioma according to ICD O Code Children with&#xD;
             chiasmatic-hypothalamic tumors may be eligible without histological diagnosis, if&#xD;
             neuroradiologic findings meet unequivocal criteria for the presence of a low grade&#xD;
             glioma.&#xD;
&#xD;
          -  Primary tumor localization: intracranial and/or spinal cord.&#xD;
&#xD;
          -  Dissemination: Children presenting with disseminated low grade glioma will be eligible&#xD;
             for the study.&#xD;
&#xD;
          -  Associated conditions: Children are eligible for the trial regardless of the presence&#xD;
             of associated genetic disease: Neurofibromatosis NF I will be the prominent one, all&#xD;
             children with NF I are entered into the study arm III in case of an indication for&#xD;
             non-surgical therapy. Other conditions like Tuberous Sclerosis etc. should be&#xD;
             registered and their impact on the course of disease and/or therapy be followed.&#xD;
&#xD;
          -  Primary tumor diagnosis: The tumor should not be pretreated with chemotherapy or&#xD;
             radiotherapy.&#xD;
&#xD;
          -  Informed consent: The patient and/or his legal guardian ( parents ) have to have&#xD;
             declared their written informed consent to the study.&#xD;
&#xD;
        Randomization: All eligible patients without Neurofibromatosis NF I receiving chemotherapy&#xD;
        as their fist non-surgical therapy are eligible for randomization.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Primary tumor localization: diffuse intrinsic tumors of the pons, even if&#xD;
             histologically an Astrocytoma I° or II° is diagnosed.&#xD;
&#xD;
        Exception: pontine glioma II° in NF I patients may be entered into the study.&#xD;
&#xD;
          -  Special diagnosis: Patients presenting with rare intracranial neoplasms of low grade&#xD;
             malignancy, but non-glial origin may be followed according to the low grade glioma&#xD;
             strategy but they are not subject of this therapy trial. Their data may be registered&#xD;
             however, to learn about those therapeutic interventions which may prove useful to&#xD;
             these patients and to develop separate strategies in the future. Choroid plexus&#xD;
             papilloma should be entered into the SIOP-CPT study.&#xD;
&#xD;
          -  Pretreatment: Children treated with chemo- or radiotherapy prior to entering the study&#xD;
             will be evaluated separately. (Previous treatment with steroids is not considered a&#xD;
             chemotherapeutic treatment.)&#xD;
&#xD;
          -  Preexisting impairments of health status, making the conduct of the study impossible&#xD;
             or ethically unwise.&#xD;
&#xD;
          -  Evidence of pregnancy or lactation period.&#xD;
&#xD;
        Participation in another clinical study: In case the patient participates in another&#xD;
        clinical study simultaneously to being enrolled in the study SIOP-LGG 2004, which is not&#xD;
        interfering with the present treatment strategy ( e.g. endocrinologic study ), this should&#xD;
        be known to the national study chairmen.&#xD;
&#xD;
        Medication: Concomitant medication for associated or other conditions ( e.g. hormone&#xD;
        replacement, anticonvulsants ), not containing cytostatic drugs, should be recorded, but is&#xD;
        no exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Gnekow</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Augsburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allg. Krankenhaus der Stadt Wien Universitaets-Kinderklinik</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>DOH-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tromso</name>
      <address>
        <city>Tromso</city>
        <zip>N-9037</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Health Institute</name>
      <address>
        <city>Warsaw</city>
        <zip>04-736</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Joao</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <results_reference>
    <citation>Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio Perilongo, Grill J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Giangaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De Salvo GL; of the Low Grade Glioma Consortium and the participating centers. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final report. Eur J Cancer. 2017 Aug;81:206-225. doi: 10.1016/j.ejca.2017.04.019. Epub 2017 Jun 22. Erratum in: Eur J Cancer. 2017 Dec 13;:.</citation>
    <PMID>28649001</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2006</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Societe Internationale d'Oncologie Pediatrique</investigator_affiliation>
    <investigator_full_name>Astrid K. Gnekow</investigator_full_name>
    <investigator_title>Chairlady</investigator_title>
  </responsible_party>
  <keyword>recurrent childhood brain stem glioma</keyword>
  <keyword>untreated childhood brain stem glioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>childhood spinal cord neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

